Profile data is unavailable for this security.
About the company
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.
- Revenue in USD (TTM)0.00
- Net income in USD-30.83m
- Incorporated2019
- Employees13.00
- LocationGalecto Inc75 State Street, Suite 100BOSTON 02109United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://galecto.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indaptus Therapeutics Inc | 0.00 | -14.98m | 17.80m | 7.00 | -- | 1.90 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
Cocrystal Pharma Inc | 0.00 | -17.98m | 17.80m | 12.00 | -- | 0.6748 | -- | -- | -1.90 | -1.90 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -49.89 | -50.94 | -53.19 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
Aytu Biopharma Inc | 98.50m | -18.00m | 17.87m | 150.00 | -- | 0.544 | -- | 0.1815 | -4.06 | -4.06 | 20.97 | 5.90 | 0.7224 | 2.79 | 3.59 | 656,653.30 | -13.20 | -33.56 | -25.46 | -52.81 | 63.24 | 56.89 | -18.27 | -73.81 | 0.9094 | -0.4382 | 0.3281 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
Pharmacyte Biotech Inc | 0.00 | -14.82m | 18.40m | 2.00 | -- | 0.5912 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
Raphael Pharmaceutical Inc | 0.00 | -1.28m | 18.66m | 0.00 | -- | 69.30 | -- | -- | -0.0799 | -0.0799 | 0.00 | 0.0144 | 0.00 | -- | -- | -- | -382.14 | -- | -688.47 | -- | -- | -- | -- | -- | -- | -106.00 | 0.1246 | -- | -- | -- | 61.76 | -- | -- | -- |
Flora Growth Corp | 76.07m | -47.36m | 18.72m | 97.00 | -- | 2.04 | -- | 0.246 | -6.62 | -7.97 | 10.04 | 0.7167 | 1.45 | 6.76 | 31.13 | 784,237.10 | -89.22 | -- | -130.91 | -- | 23.32 | -- | -61.35 | -- | 0.7897 | -- | 0.2317 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
KALA BIO Inc | 0.00 | -42.20m | 18.91m | 43.00 | -- | 2.47 | -- | -- | -17.94 | -17.94 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | -59.12 | -57.83 | -77.62 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.78 | 0.82 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
Galecto Inc | 0.00 | -30.83m | 18.98m | 13.00 | -- | 0.6741 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
GlycoMimetics Inc | 10.00k | -37.28m | 19.21m | 35.00 | -- | -- | -- | 1,920.62 | -0.5791 | -0.5791 | 0.0002 | -- | 0.0002 | -- | -- | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Bioxytran Inc | 0.00 | -4.30m | 19.25m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
Neurobo Pharmaceuticals Inc | 0.00 | -12.47m | 19.60m | 8.00 | -- | 1.17 | -- | -- | -2.71 | -2.71 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -44.29 | -95.57 | -64.66 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
Evaxion Biotech A/S - ADR | 73.00k | -22.13m | 19.66m | 49.00 | -- | -- | -- | 269.33 | -81.29 | -81.29 | 0.2665 | -1.25 | 0.0042 | -- | 0.091 | 1,489.80 | -126.74 | -100.11 | -183.85 | -131.65 | -- | -- | -30,308.22 | -131,560.30 | -- | -30.92 | 1.77 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
Zivo Bioscience Inc | 27.65k | -7.78m | 19.76m | 8.00 | -- | -- | -- | 714.69 | -4.62 | -4.62 | 0.0163 | -0.9259 | 0.0206 | -- | -- | 3,456.25 | -580.66 | -376.60 | -- | -- | 41.99 | -- | -28,127.23 | -96,315.32 | -- | -97.39 | -- | -- | -- | -- | 11.07 | -- | -- | -- |
Goldenwell Biotech Inc | 2.34k | -116.90k | 19.80m | -- | -- | 233.71 | -- | 8,461.54 | -0.0012 | -0.0012 | 0.00002 | 0.0009 | 0.0098 | 0.0071 | -- | -- | -49.07 | -- | -52.16 | -- | 47.01 | -- | -4,995.73 | -- | 37.75 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
Biomx Inc | 0.00 | -26.17m | 19.88m | 58.00 | -- | 5.37 | -- | -- | -0.5433 | -0.5433 | 0.00 | 0.067 | 0.00 | -- | -- | 0.00 | -74.18 | -- | -101.74 | -- | -- | -- | -- | -- | -- | -21.95 | 0.7841 | -- | -- | -- | 7.59 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Renaissance Technologies LLCas of 31 Dec 2023 | 406.97k | 1.50% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 212.69k | 0.78% |
Geode Capital Management LLCas of 31 Dec 2023 | 208.33k | 0.77% |
Bridgeway Capital Management LLCas of 31 Dec 2023 | 123.10k | 0.45% |
Two Sigma Securities LLCas of 31 Dec 2023 | 96.93k | 0.36% |
Citadel Securities LLCas of 31 Dec 2023 | 59.77k | 0.22% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 48.97k | 0.18% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 44.91k | 0.17% |
NFS Netfonds Financial Service GmbHas of 30 Sep 2023 | 36.90k | 0.14% |
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Dec 2023 | 30.40k | 0.11% |